28th May 2021 11:29
(Alliance News) - Avacta Group PLC on Friday noted about its ongoing CE mark submission for its SARS-CoV-2 antigen lateral flow test to the Medicines and Healthcare products Regulatory Agency.
"To date, neither Avacta nor Mologic have received any update from the MHRA. Avacta will update the market when it is in a position to do so," Avacta said Friday.
Avacta is partnering with Mologic Ltd for the test.
Shares in Avacta were slightly lower in London on Friday at 243.85 pence each.
On May 10, the Yorkshire-based drug and diagnostic equipment developer submitted the test to the UK regulator and said at the time it expected confirmation "in the coming days".
The test has been shown to be more sensitive than lateral flow tests currently on the market, particularly for lower viral loads, Avacta said.
In mid-April, speaking to Alliance News, Chief Executive Alastair Smith said the company is looking at getting the test approved in the US as well.
By Paul McGowan; [email protected];
Copyright 2021 Alliance News Limited. All Rights Reserved.
Related Shares:
Avacta Group